Literature DB >> 23890015

Clinical features and sera anti-aquaporin 4 antibody positivity in patients with demyelinating disorders of the central nervous system from Tianjin, China.

Chun-Sheng Yang1, Da-Qi Zhang, Jing-Hua Wang, Wei-Na Jin, Min-Shu Li, Jie Liu, Cun-Jin Zhang, Ting Li, Fu-Dong Shi, Li Yang.   

Abstract

AIMS: To investigate the clinical characteristics and sera anti-aquaporin 4 (AQP4) antibody positivity in patients with inflammatory demyelinating disorders (IDDs) of the central nervous system (CNS) in Tianjin, China.
METHODS: We retrospectively evaluated 234 patients with IDDs including neuromyelitis optica (NMO), recurrent optic neuritis (rON), longitudinally extensive transverse myelitis (LETM), clinically isolated syndrome (CIS), and multiple sclerosis (MS) groups. Sera from 217 patients were determined for AQP4-Ab. The clinical characteristics and sera anti-AQP4 positivity were compared.
RESULTS: The IDDS comprised 63 MS, 51 NMO, 56 LETM, 10 rON, and 54 CIS. Compared with MS, NMO had a higher frequency of occurrence in women, intractable hiccup and nausea (IHN), medullospinal lesion, longitudinally extensive spinal cord lesions (LESCL) and bilateral ON, disease onset at a later age, and worsening residual disability. AQP4-Ab-positive rates were 84.1% and 69% in NMO and NMO spectrum disorders (NMOSD), respectively, whereas it was undetectable in all of the MS sera samples.
CONCLUSIONS: We comprehensively contrast the distinct clinical features of MS, NMO, and NMOSD in our center. A sensitive AQP4-Ab assay is necessary for the early diagnosis of NMOSD in our patients. Neither medullospinal lesion nor IHN is unique in NMO.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  Anti-aquaporin 4 antibody; Chinese; Clinical features; Multiple sclerosis; Neuromyelitis optica

Mesh:

Substances:

Year:  2013        PMID: 23890015      PMCID: PMC6492993          DOI: 10.1111/cns.12156

Source DB:  PubMed          Journal:  CNS Neurosci Ther        ISSN: 1755-5930            Impact factor:   5.243


  10 in total

1.  Normal-Appearing Cerebellar Damage in Neuromyelitis Optica Spectrum Disorder.

Authors:  J Sun; N Zhang; Q Wang; X Zhang; W Qin; L Yang; F-D Shi; C Yu
Journal:  AJNR Am J Neuroradiol       Date:  2019-06-20       Impact factor: 3.825

2.  The clinical profile of NMOSD in Australia and New Zealand.

Authors:  Wajih Bukhari; Laura Clarke; Cullen O'Gorman; Elham Khalilidehkordi; Simon Arnett; Kerri M Prain; Mark Woodhall; Roger Silvestrini; Christine S Bundell; Sudarshini Ramanathan; David Abernethy; Sandeep Bhuta; Stefan Blum; Mike Boggild; Karyn Boundy; Bruce J Brew; Wallace Brownlee; Helmut Butzkueven; William M Carroll; Celia Chen; Alan Coulthard; Russell C Dale; Chandi Das; Keith Dear; Marzena J Fabis-Pedrini; David Fulcher; David Gillis; Simon Hawke; Robert Heard; Andrew P D Henderson; Saman Heshmat; Suzanne Hodgkinson; Sofia Jimenez-Sanchez; Trevor J Kilpatrick; John King; Chris Kneebone; Andrew J Kornberg; Jeannette Lechner-Scott; Ming-Wei Lin; Christopher Lynch; Richard A L Macdonnell; Deborah F Mason; Pamela A McCombe; Jennifer Pereira; John D Pollard; Stephen W Reddel; Cameron Shaw; Judith Spies; James Stankovich; Ian Sutton; Steve Vucic; Michael Walsh; Richard C Wong; Eppie M Yiu; Michael H Barnett; Allan G Kermode; Mark P Marriott; John Parratt; Mark Slee; Bruce V Taylor; Ernest Willoughby; Robert J Wilson; Fabienne Brilot; Angela Vincent; Patrick Waters; Simon A Broadley
Journal:  J Neurol       Date:  2020-01-31       Impact factor: 4.849

3.  Comparative clinical characteristics of neuromyelitis optica spectrum disorders with and without medulla oblongata lesions.

Authors:  Yanqiang Wang; Lei Zhang; Bingjun Zhang; Yongqiang Dai; Zhuang Kang; Ciyong Lu; Wei Qiu; Xueqiang Hu; Zhengqi Lu
Journal:  J Neurol       Date:  2014-03-09       Impact factor: 4.849

4.  Association Between the Single Nucleotide Polymorphism and the Level of Aquaporin-4 Protein Expression in Han and Minority Chinese with Inflammatory Demyelinating Diseases of the Central Nervous System.

Authors:  Lan Chu; Qingqing Dai; Zhu Xu; Dian He; Hao Wang; Qingsong Wang; Yifan Zhang; Yingwu Zhu; Yuan Li; Gang Cai; Krantic Slavica; Kermode Allan
Journal:  Mol Neurobiol       Date:  2015-04-18       Impact factor: 5.590

5.  Gray Matter Volume Reduction Is Associated with Cognitive Impairment in Neuromyelitis Optica.

Authors:  Q Wang; N Zhang; W Qin; Y Li; Y Fu; T Li; J Shao; L Yang; F-D Shi; C Yu
Journal:  AJNR Am J Neuroradiol       Date:  2015-09-03       Impact factor: 3.825

6.  The prevalence of anti-neurofascin-155 antibodies in patients with neuromyelitis optica spectrum disorders.

Authors:  Sheng-Hui Chang; Jing Wang; Xu Zhang; Ning Zhao; Kun Jia; Ming Yi; Qiu-Xia Zhang; Hui Zhai; Xiao-Wen Li; Chun-Sheng Yang; Li Yang; Lin-Jie Zhang
Journal:  Clin Exp Immunol       Date:  2021-06-07       Impact factor: 5.732

7.  Comparison of clinical characteristics between neuromyelitis optica spectrum disorders with and without spinal cord atrophy.

Authors:  Yanqiang Wang; Aimin Wu; Xiaoyu Chen; Lei Zhang; Yinyao Lin; Shaoyang Sun; Wei Cai; Bingjun Zhang; Zhuang Kang; Wei Qiu; Xueqiang Hu; Zhengqi Lu
Journal:  BMC Neurol       Date:  2014-12-20       Impact factor: 2.474

8.  Blood Brain Barrier Permeability Could Be a Biomarker to Predict Severity of Neuromyelitis Optica Spectrum Disorders: A Retrospective Analysis.

Authors:  Ying Wang; Mingqin Zhu; Caiyun Liu; Jinming Han; Wenjuan Lang; Yang Gao; Chao Lu; Shuang Wang; Shuai Hou; Nannan Zheng; Dong Wang; Yang Chen; Yu Zhang; Hong-Liang Zhang; Jie Zhu
Journal:  Front Neurol       Date:  2018-08-07       Impact factor: 4.003

9.  Relapse of neuromyelitis optica associated with oral progestin.

Authors:  Li-Min Li; Chao Zhang; Lin-Jie Zhang; Hui-Yue Guo; Chun-Sheng Yang; Rui Zhang; Yu-Jing Li; Fu-Dong Shi; Li Yang
Journal:  J Neurol Neurosurg Psychiatry       Date:  2017-10-09       Impact factor: 10.154

10.  Neuromyelitis optica spectrum disorders with and without connective tissue disorders.

Authors:  Chun-Sheng Yang; Qiu Xia Zhang; Sheng Hui Chang; Lin Jie Zhang; Li Min Li; Yuan Qi; Jing Wang; Zhi Hua Sun; Nannan Zhangning; Li Yang; Fu-Dong Shi
Journal:  BMC Neurol       Date:  2018-10-24       Impact factor: 2.474

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.